Related Experiment Videos
Assessment of mutagenicity tests
Archives of Toxicology. Supplement. = Archiv Fur Toxikologie. Supplement
|January 1, 1980
Summary
Short-term tests identify potential mutagens, but mammalian in vivo tests are crucial for human mutagenic hazard assessment. Benefit/risk analysis determines if drugs with reproducible mutagenicity findings should be withdrawn.
Area of Science:
- Toxicology
- Genetics
- Pharmacology
Background:
- Short-term tests are utilized to screen chemicals for mutagenic potential.
- Mammalian in vivo studies are essential for evaluating human mutagenic risks.
- Establishing mutagenicity requires reproducible findings from conclusive tests.
Purpose of the Study:
- To outline the process for evaluating chemical mutagenicity.
- To emphasize the necessity of in vivo testing for human risk assessment.
- To describe the decision-making framework for drug market withdrawal based on mutagenicity.
Main Methods:
- Utilizing short-term tests for initial mutagen screening.
- Conducting mammalian in vivo tests for definitive hazard assessment.
- Performing benefit/risk analyses for drugs with identified mutagenicity.
Main Results:
- Short-term tests can indicate potential mutagenicity.
- In vivo mammalian tests provide conclusive data on mutagenic hazards.
- Reproducible mutagenicity findings necessitate further evaluation.
Conclusions:
- A tiered testing approach, from in vitro to in vivo, is critical for chemical safety.
- Benefit/risk assessments are paramount in regulatory decisions regarding drug safety.
- Drugs exhibiting significant mutagenic risks may require market withdrawal.